TARGET Protein:增加肠内蛋白给予对危重成人临床结局的影响——一项整群随机、横断面、双交叉临床试验的统计分析计划
TARGET Protein试验在澳大利亚和新西兰8个ICU开展整群随机、横断面、双交叉、开放标签、注册库嵌入的实用性临床试验,比较增加肠内蛋白与常规剂量蛋白对危重成人临床结局的影响;主要结局为第90天无指数医院住院且存活的天数,已完成3412例患者入组,数据链接正在进行中。
要点
- TARGET Protein为整群随机、双交叉设计,8个ICU按1:1随机接受增加蛋白或常规剂量肠内蛋白。
- 主要结局为第90天无指数医院住院且存活的天数,所有统计模型均考虑整群随机交叉设计以正确估计95%CI。
- 试验已完成3412例患者入组,数据链接正在进行中。
核心结论
- 该统计分析计划有助于TARGET Protein试验的透明报告,并降低潜在选择性报告偏倚的风险。
研究设计与样本
- TARGET Protein为在澳大利亚和新西兰开展的整群随机、横断面、双交叉、开放标签、注册库嵌入的实用性临床试验。
- 8个ICU按1:1随机接受含较高剂量肠内蛋白(增加蛋白)或常规剂量蛋白的肠内配方。
- 每个ICU接受一种试验配方3个月后转换为另一种配方,该序列重复,总试验时长为12个月。
- 试验入组已完成,共纳入3412例患者,数据链接正在进行中。
主要发现
- 主要结局为第90天无指数医院住院且存活的天数。
- 次要结局包括第90天存活患者比例、仅存活者分析的第90天无指数医院住院天数、有创通气持续时间、ICU和住院时长、气管造口置入发生率、肾脏替代治疗及出院去向。
局限性
- 原文未报告局限性。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
BACKGROUND: The TARGET Protein trial will evaluate the effect of greater enteral protein delivery (augmented protein) on clinical outcomes of critically ill adult patients when compared to usual care. OBJECTIVE: To describe the statistical analysis plan for the TARGET Protein trial. METHODS: TARGET Protein is a cluster randomized, cross-sectional, double cross-over, open-label, registry-embedded, pragmatic clinical trial conducted across Australia and New Zealand. The trial randomized eight intensive care units (ICU) to receive enteral formula containing either higher dose enteral protein (augmented protein) or usual dose protein in a 1:1 ratio. Each ICU received one trial formula for a 3-month period and then switched to the alternate formulae. This sequence was repeated, for a total trial length of 12 months. The primary outcome is the number of days free of the index hospital and alive at day 90. Secondary outcomes include proportion of patients alive at day 90, survivor-only analysis of days free of the index hospital at day 90, duration of invasive ventilation, ICU and hospital length of stay, incidence of tracheostomy insertion, renal replacement therapy, and discharge destination. The statistical methods and models which will be used to estimate the effects for the primary and secondary outcomes are described. All statistical models will account for the cluster-randomized cross-over design to ensure correct estimation of the 95% confidence intervals. Trial enrolment is complete with 3412 patients enrolled. Data linkage is ongoing. CONCLUSION: This statistical analysis plan enables transparent reporting of the TARGET Protein trial. It will reduce the risk of potential selective reporting biases. TRIAL REGISTRATION: Australian New Zealand Clinical Trials Registry (ACTRN12621001484831). Registered on November 1, 2021.
引用
- Zaloumis S, Summers MJ, Presneill JJ, et al. TARGET Protein: the effect of augmented administration of enteral protein to critically ill adults on clinical outcomes-statistical analysis plan for a cluster randomized, cross-sectional, double cross-over, clinical trial. Trials. 2025. PMID: 39915843. doi:10.1186/s13063-025-08759-0
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。